EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

A Pilot, Predictive Surveillance Model in Pharmacovigilance Using Machine Learning Approaches

Rosa De Abreu Ferreira, Sheng Zhong, Charlotte Moureaud iD, Michelle T Le, Adrienne Rothstein, Xiaomeng Li, Li Wang, Meenal Patwardhan

Advances in Therapy · 2024-06 · 41 (6) · 2435-2445

DOI: 10.1007/s12325-024-02870-5 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advances in Therapy, online erschienen am 05.05.2024. Verfasst von Rosa De Abreu Ferreira und 7 weiteren Autor:innen. Beteiligte Einrichtung: Medical Safety Evaluation, Pharmacovigilance and Patient Safety, Epidemiology, and Research and Development Quality Assurance, AbbVie, Inc., North Ch…. Hauptthemen laut MEDLINE: Pharmacovigilance, Machine Learning. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: The identification of a new adverse event (AE) caused by a drug product is one of the key activities in the pharmaceutical industry to ensure the safety profile of a drug product. Machine learning (ML) has the potential to assist with signal detection and supplement traditional pharmacovigilance (PV) surveillance methods. This pilot ML modeling study was designed to detect potential safety signals for two AbbVie products and test the model's capability of detecting safety signals earlier than humans. METHODS: Drug X, a mature product with post-marketing data, and Drug Y, a recently approved drug in another therapeutic area, were selected. Gradient boosting-based ML approaches (e.g., XGBoost) were applied as the main modeling strategy. RESULTS: For Drug X, eight true signals were present in the test set. Among 12 potential new signals generated, four were true signals with a 50.0% sensitivity rate and a 33.3% positive predictive value (PPV) rate. Among the remaining eight potential new signals, one was confirmed as a signal and detected six months earlier than humans. For Drug Y, nine true signals were present in the test set. Among 13 potential new signals generated, five were true signals with a 55.6% sensitivity rate and a 38.5% PPV rate. Among the remaining eight potential new signals, none were confirmed as true signals upon human review. CONCLUSION: This model demonstrated acceptable accuracy for safety signal detection and potential for earlier detection when compared to humans. Expert judgment, flexibility, and critical thinking are essential human skills required for the final, accurate assessment of adverse event cases.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PharmacovigilanceMachine LearningHumansPilot ProjectsAdverse Drug Reaction Reporting SystemsDrug-Related Side Effects and Adverse Reactions

Stichwörter der Autor:innen

Adverse drug reactionArtificial intelligenceMachine learningPharmacovigilanceSafety surveillanceSignal detectionSignal prediction

Autor:innen und Institutionen

  • Medical Safety Evaluation, Pharmacovigilance and Patient Safety, Epidemiology, and Research and Development Quality Assurance, AbbVie, Inc., North Chicago, IL, USA.
  • Statistical Sciences and Analytics, Data and Statistical Sciences, AbbVie, Inc., North Chicago, IL, USA.
  • Safety Data Sciences, Pharmacovigilance and Patient Safety, Epidemiology, and Research and Development Quality Assurance, AbbVie, Inc., North Chicago, IL, USA. charlotte.moureaud@abbvie.com.
  • Medication Safety Fellow, Purdue University College of Pharmacy, West Lafayette, IN, USA.
  • Safety Data Sciences, Pharmacovigilance and Patient Safety, Epidemiology, and Research and Development Quality Assurance, AbbVie, Inc., North Chicago, IL, USA.

ORCID-Profile: Charlotte Moureaud

Zitieren

APA

De Abreu Ferreira, R., Zhong, S., Moureaud, C., Le, M. T., Rothstein, A., Li, X., Wang, L., & Patwardhan, M. (2024). A Pilot, Predictive Surveillance Model in Pharmacovigilance Using Machine Learning Approaches. Advances in Therapy, 41(6), 2435-2445. https://doi.org/10.1007/s12325-024-02870-5

Vancouver

De Abreu Ferreira R, Zhong S, Moureaud C, Le MT, Rothstein A, Li X, et al. A Pilot, Predictive Surveillance Model in Pharmacovigilance Using Machine Learning Approaches. Advances in Therapy. 2024;41(6):2435-2445. doi:10.1007/s12325-024-02870-5

BibTeX
@article{DeAbreuFerreira2024,
  author = {De Abreu Ferreira, Rosa and Zhong, Sheng and Moureaud, Charlotte and Le, Michelle T and Rothstein, Adrienne and Li, Xiaomeng and Wang, Li and Patwardhan, Meenal},
  title = {A Pilot, Predictive Surveillance Model in Pharmacovigilance Using Machine Learning Approaches},
  journal = {Advances in Therapy},
  year = {2024},
  volume = {41},
  number = {6},
  pages = {2435--2445},
  doi = {10.1007/s12325-024-02870-5}
}
Kostenlos starten →